Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEOBiotechnology
-$0.05 today
- Market cap
- $244.23M
- Beta
- 1.39
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.08
Volume 1.76M
Average 0.86M
Returns on capital
Lexeo Therapeutics, Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.5%
avg 8.9%
ROIC
-42.9%
avg -50.6%
ROA
-37.2%
avg -44.5%
Analysis
ROA is currently the strongest return metric at -37.2% versus its period average of -44.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jose Manuel Otero | Chief Operating Officer | USD 2.99M | 47 | 54.75K | 0.07% |
R. Nolan Townsend | Chief Executive Officer & Director | USD 991.47K | 45 | — | — |
Louis Tamayo | Chief Financial Officer & Principal Accounting Officer | USD 638.9K | 49 | — | — |
Ronald G. Crystal | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board | — | — | — | — |
Ashley Kaplowitz | Head of Capital Markets | — | — | — | — |
Keith Wonnacott | Senior Vice President of Regulatory Affairs | — | — | — | — |
Narinder Bhalla FACC FSCAI | Chief Medical Officer | — | 62 | — | — |
Ryan McHenry | Vice President & Corporate Controller | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 24, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$720,693.49
Net Transaction Value
−$720,693.49
Net selling
Most Active
Townsend Richard Nolan
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 18, 26Aug 18, 2026 | Otero Jose Manuel Direct | Sell | $6.5K$6,464.06 |
| Aug 18, 26Aug 18, 2026 | Tamayo Louis Edward Direct | Sell | $20.2K$20,202.53 |
| Aug 18, 26Aug 18, 2026 | Townsend Richard Nolan Direct | Sell | $16.6K$16,561.76 |
| Jul 1, 26Jul 1, 2026 | Tamayo Louis Edward Direct | Sell | $20.8K$20,838.09 |
| Jul 1, 26Jul 1, 2026 | Bhalla Narinder Pal Direct | Sell | $98.6K$98,592.52 |
| Jul 1, 26Jul 1, 2026 | Otero Jose Manuel Direct | Sell | $20.9K$20,903.68 |
| Jul 1, 26Jul 1, 2026 | Townsend Richard Nolan Direct | Sell | $116.2K$116,242.56 |
| May 18, 26May 18, 2026 | Otero Jose Manuel Direct | Sell | $6.6K$6,606.35 |
| May 18, 26May 18, 2026 | Townsend Richard Nolan Direct | Sell | $16.9K$16,926.90 |
| Apr 6, 26Apr 6, 2026 | Townsend Richard Nolan Direct | Sell | $313.1K$313,137.00 |
1–10 of 12
Summary
Insiders reported 0 buys worth $0.00 and 12 sells worth $720,693.49 over the last 12 months. That adds up to net selling of $720,693.49. Townsend Richard Nolan was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Lexeo Therapeutics, Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about LXEO's management, answered from reported figures.
Who manages LXEO?
Lexeo Therapeutics, Inc. Common Stock (LXEO) lists 8 active executives. The top listed executive is Ronald G. Crystal, Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board.
Are LXEO insiders buying or selling?
Recent insider activity shows net buying of $45.48M.
Continue the stock analysis
Jump to another research area for this company.